Skip to main content

Table 4 High throughput screening for potential compounds with anti-Zika activity (drug repurposing)

From: Zika vaccines and therapeutics: landscape analysis and challenges ahead

Study No. of drugs screened Compounds identified with anti-Zika activity Remarks
Barrows et al. [54] 774 FDA-approved agents Clofazimine, Digoxin, Gemcitabine, Ivermectin, Mefloquine, Mercaptopurine hydrate, Mycophenolic acid, Fingolimod, Mycophenolate mofetil, Dactinomycin, Bortezomib, Methoxsalen (Xanthotoxin), Azathioprine, Thioguanine, Auranofin, Sertraline, Pyrimethamine, Daptomycin, Palonosetron, Deferasirox, Micafungin, Sorafenib tosylate, Cyclosporine A, Mebendazole • Mycophenolic acid (MPA), Ivermectin, Daptomycin, Mefloquine, Palonosetron identified as having higher potency
• Daptomycin, Mefloquine, and Palonosetron are pregnancy category B drugs
Xu et al. [58] 6000 compounds,
> 2000 FDA-approved agents
Niclosamide, Emricasan, 10 structurally unrelated inhibitors of CDK • Emricasan is an inhibitor of caspase-3 activity but uncertain if a capase-3 inhibitor with anti-inflammatory properties impacts development of unborn fetus